 Kennon Heard
Concepts (628)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acetaminophen | 37 | 2022 | 241 | 9.420 |
Why?
| | Chemical and Drug Induced Liver Injury | 14 | 2022 | 136 | 5.340 |
Why?
| | Analgesics, Non-Narcotic | 20 | 2022 | 118 | 5.100 |
Why?
| | Drug Overdose | 30 | 2022 | 271 | 4.930 |
Why?
| | Emergency Service, Hospital | 39 | 2020 | 1819 | 3.950 |
Why?
| | Poisoning | 17 | 2017 | 127 | 3.500 |
Why?
| | Poison Control Centers | 10 | 2018 | 99 | 3.020 |
Why?
| | Alanine Transaminase | 13 | 2022 | 148 | 3.000 |
Why?
| | Cannabis | 9 | 2020 | 340 | 3.000 |
Why?
| | Acetylcysteine | 10 | 2020 | 146 | 2.970 |
Why?
| | Cocaine | 10 | 2011 | 168 | 2.830 |
Why?
| | Prescription Drugs | 9 | 2018 | 114 | 2.610 |
Why?
| | Analgesics, Opioid | 7 | 2020 | 759 | 1.770 |
Why?
| | Legislation, Drug | 5 | 2017 | 68 | 1.760 |
Why?
| | Antidotes | 9 | 2020 | 156 | 1.720 |
Why?
| | Cysteine | 4 | 2017 | 200 | 1.630 |
Why?
| | Antipsychotic Agents | 7 | 2019 | 195 | 1.560 |
Why?
| | Marijuana Use | 4 | 2021 | 157 | 1.480 |
Why?
| | Medication Errors | 5 | 2015 | 98 | 1.370 |
Why?
| | Male | 101 | 2022 | 60403 | 1.360 |
Why?
| | Cocaine-Related Disorders | 5 | 2011 | 109 | 1.300 |
Why?
| | Toxicology | 4 | 2021 | 36 | 1.270 |
Why?
| | Humans | 148 | 2022 | 117633 | 1.260 |
Why?
| | Emergency Medicine | 6 | 2019 | 257 | 1.250 |
Why?
| | Drug Packaging | 2 | 2017 | 45 | 1.250 |
Why?
| | Pain | 9 | 2020 | 796 | 1.240 |
Why?
| | Adult | 73 | 2022 | 32118 | 1.210 |
Why?
| | Female | 95 | 2022 | 63247 | 1.200 |
Why?
| | Medication Reconciliation | 2 | 2016 | 25 | 1.150 |
Why?
| | Dose-Response Relationship, Drug | 16 | 2017 | 2106 | 1.070 |
Why?
| | Spider Bites | 5 | 2019 | 9 | 1.060 |
Why?
| | Antidepressive Agents, Tricyclic | 5 | 2014 | 31 | 1.050 |
Why?
| | Akathisia, Drug-Induced | 2 | 2020 | 8 | 1.020 |
Why?
| | Antivenins | 5 | 2019 | 58 | 1.000 |
Why?
| | Thiazoles | 4 | 2009 | 118 | 0.990 |
Why?
| | Spider Venoms | 4 | 2019 | 12 | 0.970 |
Why?
| | Middle Aged | 54 | 2022 | 28659 | 0.960 |
Why?
| | Young Adult | 30 | 2020 | 11077 | 0.950 |
Why?
| | Benzodiazepines | 5 | 2011 | 119 | 0.940 |
Why?
| | Heart Arrest | 8 | 2018 | 327 | 0.920 |
Why?
| | Referral and Consultation | 2 | 2020 | 671 | 0.920 |
Why?
| | Seizures | 6 | 2011 | 343 | 0.900 |
Why?
| | Physostigmine | 2 | 2020 | 11 | 0.880 |
Why?
| | Muscarinic Antagonists | 2 | 2022 | 31 | 0.870 |
Why?
| | Lorazepam | 2 | 2020 | 26 | 0.870 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 312 | 0.870 |
Why?
| | Delirium | 2 | 2020 | 70 | 0.860 |
Why?
| | Emergency Treatment | 4 | 2015 | 114 | 0.860 |
Why?
| | Piperazines | 4 | 2009 | 323 | 0.860 |
Why?
| | Black Widow Spider | 4 | 2019 | 10 | 0.860 |
Why?
| | Medical History Taking | 3 | 2018 | 130 | 0.840 |
Why?
| | Dopamine Uptake Inhibitors | 3 | 2011 | 61 | 0.840 |
Why?
| | Suicide, Attempted | 5 | 2012 | 298 | 0.830 |
Why?
| | Abdominal Pain | 2 | 2019 | 142 | 0.800 |
Why?
| | Buprenorphine | 2 | 2020 | 106 | 0.800 |
Why?
| | Retrospective Studies | 30 | 2022 | 12331 | 0.800 |
Why?
| | Diphenhydramine | 3 | 2020 | 33 | 0.800 |
Why?
| | Back Pain | 1 | 2020 | 41 | 0.780 |
Why?
| | Vasoconstrictor Agents | 4 | 2009 | 124 | 0.780 |
Why?
| | Hospitals, Pediatric | 4 | 2018 | 488 | 0.770 |
Why?
| | Anti-Arrhythmia Agents | 4 | 2014 | 155 | 0.770 |
Why?
| | Patient Handoff | 1 | 2020 | 28 | 0.760 |
Why?
| | Free Radical Scavengers | 2 | 2011 | 90 | 0.750 |
Why?
| | Social Work | 1 | 2020 | 62 | 0.740 |
Why?
| | Ketorolac | 1 | 2019 | 21 | 0.730 |
Why?
| | Haloperidol | 1 | 2019 | 39 | 0.730 |
Why?
| | Pharmacoepidemiology | 1 | 2018 | 20 | 0.710 |
Why?
| | Tertiary Care Centers | 3 | 2017 | 130 | 0.700 |
Why?
| | Substance-Related Disorders | 5 | 2012 | 949 | 0.690 |
Why?
| | Gastric Lavage | 3 | 2009 | 11 | 0.690 |
Why?
| | Vomiting | 6 | 2019 | 124 | 0.680 |
Why?
| | Immunoglobulin Fab Fragments | 4 | 2019 | 68 | 0.670 |
Why?
| | Colorado | 15 | 2021 | 4401 | 0.670 |
Why?
| | Hypotension | 2 | 2022 | 127 | 0.660 |
Why?
| | Cannabinoids | 3 | 2017 | 116 | 0.660 |
Why?
| | Drug Storage | 2 | 2017 | 64 | 0.650 |
Why?
| | Child | 26 | 2020 | 18649 | 0.650 |
Why?
| | Pulmonary Embolism | 3 | 2021 | 173 | 0.640 |
Why?
| | Accidents, Home | 1 | 2017 | 41 | 0.630 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2007 | 73 | 0.630 |
Why?
| | Plant Preparations | 2 | 2015 | 21 | 0.630 |
Why?
| | Medical Marijuana | 2 | 2019 | 114 | 0.620 |
Why?
| | Calcium Gluconate | 1 | 2016 | 5 | 0.620 |
Why?
| | Hypocalcemia | 1 | 2016 | 27 | 0.610 |
Why?
| | Quaternary Ammonium Compounds | 1 | 2016 | 48 | 0.610 |
Why?
| | Health Records, Personal | 1 | 2016 | 23 | 0.590 |
Why?
| | Emergency Medical Services | 4 | 2016 | 541 | 0.590 |
Why?
| | Prospective Studies | 17 | 2021 | 6422 | 0.590 |
Why?
| | Mobile Applications | 1 | 2018 | 147 | 0.590 |
Why?
| | Nonprescription Drugs | 4 | 2016 | 70 | 0.580 |
Why?
| | Antidepressive Agents | 2 | 2012 | 203 | 0.570 |
Why?
| | Fat Emulsions, Intravenous | 2 | 2014 | 31 | 0.570 |
Why?
| | Blood Proteins | 1 | 2017 | 247 | 0.570 |
Why?
| | Treatment Outcome | 18 | 2020 | 9353 | 0.560 |
Why?
| | Prescription Drug Misuse | 1 | 2015 | 41 | 0.550 |
Why?
| | Liver | 6 | 2022 | 1856 | 0.550 |
Why?
| | Child, Preschool | 13 | 2018 | 9714 | 0.540 |
Why?
| | Infant | 12 | 2018 | 8255 | 0.540 |
Why?
| | Electrocardiography | 5 | 2013 | 650 | 0.530 |
Why?
| | Asymptomatic Diseases | 2 | 2013 | 77 | 0.520 |
Why?
| | Crime | 2 | 2011 | 60 | 0.510 |
Why?
| | Observer Variation | 3 | 2010 | 326 | 0.500 |
Why?
| | Adolescent | 27 | 2020 | 18902 | 0.500 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 1 | 2013 | 28 | 0.500 |
Why?
| | Energy Drinks | 1 | 2013 | 4 | 0.500 |
Why?
| | Performance-Enhancing Substances | 1 | 2013 | 8 | 0.490 |
Why?
| | Double-Blind Method | 7 | 2020 | 1695 | 0.490 |
Why?
| | Dronabinol | 4 | 2021 | 114 | 0.480 |
Why?
| | Diet Surveys | 1 | 2013 | 76 | 0.480 |
Why?
| | Accidents | 1 | 2013 | 41 | 0.480 |
Why?
| | Plasmapheresis | 1 | 2013 | 26 | 0.480 |
Why?
| | Bradycardia | 1 | 2013 | 59 | 0.480 |
Why?
| | Phytotherapy | 1 | 2013 | 66 | 0.480 |
Why?
| | Hematemesis | 1 | 2012 | 4 | 0.480 |
Why?
| | Amphotericin B | 1 | 2013 | 37 | 0.480 |
Why?
| | Opioid-Related Disorders | 2 | 2020 | 357 | 0.480 |
Why?
| | Stomach Diseases | 1 | 2012 | 19 | 0.470 |
Why?
| | Foreign Bodies | 2 | 2011 | 94 | 0.470 |
Why?
| | Arrhythmias, Cardiac | 3 | 2022 | 328 | 0.470 |
Why?
| | beta-Alanine | 1 | 2012 | 24 | 0.470 |
Why?
| | Ethers | 1 | 2012 | 15 | 0.470 |
Why?
| | Sulfonylurea Compounds | 2 | 2010 | 46 | 0.470 |
Why?
| | Aspartate Aminotransferases | 3 | 2010 | 101 | 0.470 |
Why?
| | Aged | 27 | 2019 | 20249 | 0.470 |
Why?
| | Citalopram | 1 | 2012 | 27 | 0.460 |
Why?
| | Antithrombins | 1 | 2012 | 58 | 0.460 |
Why?
| | Liver Function Tests | 7 | 2020 | 116 | 0.450 |
Why?
| | Antifungal Agents | 1 | 2013 | 130 | 0.450 |
Why?
| | Propafenone | 1 | 2011 | 2 | 0.450 |
Why?
| | C-Peptide | 2 | 2010 | 132 | 0.450 |
Why?
| | Alcohol Drinking | 4 | 2012 | 711 | 0.450 |
Why?
| | Burns | 2 | 2015 | 225 | 0.450 |
Why?
| | Disease Models, Animal | 9 | 2011 | 3799 | 0.440 |
Why?
| | Drug Administration Schedule | 5 | 2014 | 780 | 0.440 |
Why?
| | Thiophenes | 1 | 2012 | 104 | 0.440 |
Why?
| | Firesetting Behavior | 1 | 2011 | 1 | 0.440 |
Why?
| | Practice Patterns, Physicians' | 2 | 2020 | 1228 | 0.430 |
Why?
| | Clinical Enzyme Tests | 2 | 2013 | 11 | 0.430 |
Why?
| | Charcoal | 4 | 2006 | 24 | 0.430 |
Why?
| | Infusions, Intravenous | 6 | 2013 | 393 | 0.430 |
Why?
| | Benzimidazoles | 1 | 2012 | 142 | 0.430 |
Why?
| | Genetic Predisposition to Disease | 1 | 2020 | 2206 | 0.430 |
Why?
| | Temperance | 2 | 2010 | 17 | 0.430 |
Why?
| | Chemical and Drug Induced Liver Injury, Chronic | 1 | 2011 | 7 | 0.420 |
Why?
| | Administration, Intravenous | 4 | 2016 | 138 | 0.420 |
Why?
| | Brain Edema | 1 | 2011 | 61 | 0.420 |
Why?
| | Aged, 80 and over | 15 | 2018 | 6795 | 0.410 |
Why?
| | Amitriptyline | 2 | 2001 | 20 | 0.410 |
Why?
| | Cholinergic Antagonists | 1 | 2011 | 28 | 0.410 |
Why?
| | Blood Chemical Analysis | 3 | 2021 | 95 | 0.410 |
Why?
| | Liver Failure | 1 | 2011 | 82 | 0.400 |
Why?
| | Self-Injurious Behavior | 1 | 2012 | 120 | 0.400 |
Why?
| | Anaphylaxis | 2 | 2012 | 144 | 0.400 |
Why?
| | Immunologic Factors | 2 | 2019 | 230 | 0.400 |
Why?
| | Hydrofluoric Acid | 2 | 2016 | 7 | 0.400 |
Why?
| | Propylene Glycol | 1 | 2010 | 8 | 0.390 |
Why?
| | Pharmaceutical Vehicles | 1 | 2010 | 15 | 0.390 |
Why?
| | Barium | 1 | 2009 | 26 | 0.390 |
Why?
| | Acidosis, Lactic | 1 | 2010 | 27 | 0.390 |
Why?
| | Explosive Agents | 1 | 2009 | 7 | 0.390 |
Why?
| | Tachycardia, Ventricular | 1 | 2012 | 188 | 0.390 |
Why?
| | Cross-Sectional Studies | 9 | 2020 | 4630 | 0.380 |
Why?
| | Population Surveillance | 1 | 2013 | 449 | 0.380 |
Why?
| | Imines | 2 | 2022 | 8 | 0.380 |
Why?
| | Warfarin | 1 | 2010 | 139 | 0.380 |
Why?
| | Liver Diseases, Alcoholic | 2 | 2007 | 88 | 0.380 |
Why?
| | Hypokalemia | 1 | 2009 | 35 | 0.380 |
Why?
| | Iatrogenic Disease | 1 | 2010 | 48 | 0.380 |
Why?
| | Emetics | 2 | 2006 | 7 | 0.380 |
Why?
| | Surveys and Questionnaires | 4 | 2018 | 4842 | 0.370 |
Why?
| | Deception | 1 | 2009 | 18 | 0.370 |
Why?
| | Time Factors | 12 | 2020 | 6906 | 0.370 |
Why?
| | Benzoquinones | 2 | 2022 | 46 | 0.370 |
Why?
| | Length of Stay | 3 | 2020 | 1046 | 0.370 |
Why?
| | Random Allocation | 3 | 2007 | 385 | 0.370 |
Why?
| | Risk Factors | 9 | 2017 | 9124 | 0.370 |
Why?
| | Electronic Health Records | 2 | 2015 | 724 | 0.360 |
Why?
| | Oximetry | 1 | 2009 | 85 | 0.360 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 4 | 2015 | 234 | 0.360 |
Why?
| | United States | 16 | 2020 | 12768 | 0.360 |
Why?
| | Evidence-Based Medicine | 3 | 2010 | 724 | 0.350 |
Why?
| | Intellectual Disability | 1 | 2009 | 118 | 0.350 |
Why?
| | Odds Ratio | 7 | 2017 | 1038 | 0.350 |
Why?
| | Risk Assessment | 8 | 2017 | 3208 | 0.350 |
Why?
| | Point-of-Care Systems | 1 | 2010 | 158 | 0.340 |
Why?
| | Eyelashes | 1 | 2008 | 3 | 0.340 |
Why?
| | Hypothermia, Induced | 1 | 2009 | 116 | 0.340 |
Why?
| | Cyanoacrylates | 1 | 2008 | 5 | 0.340 |
Why?
| | Hypoglycemia | 2 | 2010 | 387 | 0.340 |
Why?
| | Adhesives | 1 | 2008 | 12 | 0.340 |
Why?
| | Detergents | 1 | 2008 | 46 | 0.340 |
Why?
| | Cardiovascular System | 1 | 2009 | 118 | 0.330 |
Why?
| | Reference Values | 4 | 2017 | 835 | 0.330 |
Why?
| | Brugada Syndrome | 1 | 2007 | 15 | 0.320 |
Why?
| | Polyethylene Glycols | 1 | 2012 | 572 | 0.320 |
Why?
| | Diazepam | 1 | 2007 | 31 | 0.320 |
Why?
| | Niacin | 1 | 2007 | 23 | 0.320 |
Why?
| | Clinical Laboratory Techniques | 1 | 2008 | 95 | 0.320 |
Why?
| | Animals | 20 | 2019 | 34350 | 0.320 |
Why?
| | Publishing | 1 | 2009 | 155 | 0.320 |
Why?
| | Vitamin B Complex | 1 | 2007 | 38 | 0.310 |
Why?
| | Thromboembolism | 1 | 2007 | 104 | 0.310 |
Why?
| | Mice, Inbred Strains | 4 | 2009 | 440 | 0.310 |
Why?
| | Specimen Handling | 1 | 2008 | 169 | 0.310 |
Why?
| | Pediatrics | 1 | 2015 | 1021 | 0.310 |
Why?
| | Brain Infarction | 1 | 2006 | 23 | 0.310 |
Why?
| | Analgesics | 4 | 2017 | 168 | 0.300 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2006 | 27 | 0.300 |
Why?
| | Decontamination | 1 | 2006 | 16 | 0.300 |
Why?
| | Anticoagulants | 1 | 2010 | 541 | 0.300 |
Why?
| | Nausea | 4 | 2014 | 108 | 0.290 |
Why?
| | Amiodarone | 1 | 2005 | 24 | 0.290 |
Why?
| | Self Report | 4 | 2021 | 715 | 0.290 |
Why?
| | Acute Kidney Injury | 1 | 2012 | 643 | 0.290 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2012 | 1209 | 0.290 |
Why?
| | Venous Thrombosis | 1 | 2007 | 134 | 0.290 |
Why?
| | Epilepsy | 2 | 2020 | 278 | 0.290 |
Why?
| | Intention | 1 | 2007 | 155 | 0.290 |
Why?
| | Databases, Factual | 1 | 2010 | 1145 | 0.280 |
Why?
| | Eating | 4 | 2017 | 382 | 0.280 |
Why?
| | Vasospasm, Intracranial | 1 | 2005 | 20 | 0.280 |
Why?
| | Age Factors | 7 | 2017 | 3223 | 0.280 |
Why?
| | Subarachnoid Hemorrhage | 1 | 2005 | 47 | 0.280 |
Why?
| | Sodium Nitrite | 1 | 2005 | 37 | 0.280 |
Why?
| | Diagnostic Imaging | 1 | 2007 | 292 | 0.270 |
Why?
| | Biomarkers | 7 | 2021 | 3574 | 0.270 |
Why?
| | Drug Utilization | 5 | 2014 | 181 | 0.270 |
Why?
| | Hypoglycemic Agents | 2 | 2010 | 1026 | 0.270 |
Why?
| | Coma | 2 | 2006 | 39 | 0.270 |
Why?
| | Education, Medical | 2 | 2021 | 252 | 0.260 |
Why?
| | Reproducibility of Results | 5 | 2011 | 2948 | 0.260 |
Why?
| | Insulin | 3 | 2019 | 2138 | 0.250 |
Why?
| | Hospitals, Urban | 5 | 2021 | 144 | 0.250 |
Why?
| | Anti-Anxiety Agents | 2 | 2020 | 48 | 0.250 |
Why?
| | Injections, Intraperitoneal | 4 | 2009 | 129 | 0.250 |
Why?
| | Animal Experimentation | 1 | 2003 | 5 | 0.250 |
Why?
| | Glasgow Coma Scale | 1 | 2004 | 152 | 0.250 |
Why?
| | Case-Control Studies | 4 | 2022 | 3269 | 0.240 |
Why?
| | Calcium Chloride | 1 | 2003 | 12 | 0.240 |
Why?
| | Magnesium Sulfate | 1 | 2003 | 19 | 0.240 |
Why?
| | Hospitals, Teaching | 3 | 2014 | 109 | 0.240 |
Why?
| | Fibrinolytic Agents | 2 | 2021 | 245 | 0.240 |
Why?
| | Opiate Substitution Treatment | 2 | 2020 | 80 | 0.230 |
Why?
| | Sensitivity and Specificity | 4 | 2010 | 1897 | 0.230 |
Why?
| | Desipramine | 1 | 2001 | 10 | 0.220 |
Why?
| | Umbilical Cord | 2 | 2021 | 88 | 0.220 |
Why?
| | Placebos | 2 | 2014 | 211 | 0.220 |
Why?
| | Longevity | 3 | 2009 | 187 | 0.220 |
Why?
| | Phenylurea Compounds | 1 | 2022 | 90 | 0.220 |
Why?
| | Cardiopulmonary Resuscitation | 3 | 2018 | 244 | 0.220 |
Why?
| | Narcotic Antagonists | 2 | 2020 | 150 | 0.220 |
Why?
| | Hyperthermia, Induced | 1 | 2022 | 70 | 0.220 |
Why?
| | Logistic Models | 3 | 2017 | 2018 | 0.220 |
Why?
| | Research Design | 3 | 2006 | 968 | 0.210 |
Why?
| | Confidence Intervals | 4 | 2010 | 339 | 0.210 |
Why?
| | Sinus Thrombosis, Intracranial | 1 | 2021 | 23 | 0.210 |
Why?
| | Fractures, Bone | 2 | 2017 | 343 | 0.210 |
Why?
| | Heart Atria | 1 | 2001 | 124 | 0.210 |
Why?
| | Severity of Illness Index | 1 | 2009 | 2884 | 0.210 |
Why?
| | Acute Disease | 2 | 2019 | 983 | 0.200 |
Why?
| | Lysergic Acid Diethylamide | 1 | 1999 | 2 | 0.190 |
Why?
| | Immunoglobulin Fragments | 1 | 1999 | 15 | 0.190 |
Why?
| | Droperidol | 1 | 1999 | 5 | 0.190 |
Why?
| | Lithium Carbonate | 1 | 1999 | 5 | 0.190 |
Why?
| | Wisconsin | 1 | 2020 | 92 | 0.190 |
Why?
| | Myocardial Contraction | 1 | 2001 | 349 | 0.190 |
Why?
| | Serotonin Syndrome | 1 | 1999 | 7 | 0.190 |
Why?
| | Scorpion Stings | 1 | 1999 | 1 | 0.190 |
Why?
| | Serotonin Receptor Agonists | 1 | 1999 | 32 | 0.190 |
Why?
| | Nutritive Value | 1 | 2019 | 32 | 0.190 |
Why?
| | Starch | 1 | 2019 | 22 | 0.190 |
Why?
| | Community Health Workers | 1 | 2020 | 45 | 0.190 |
Why?
| | Cannabidiol | 1 | 2020 | 55 | 0.190 |
Why?
| | Geriatric Assessment | 2 | 2011 | 182 | 0.190 |
Why?
| | Ventricular Premature Complexes | 1 | 1999 | 33 | 0.190 |
Why?
| | Mass Screening | 1 | 2007 | 1081 | 0.190 |
Why?
| | Healthy Volunteers | 2 | 2019 | 216 | 0.180 |
Why?
| | Thrombocytopenia | 1 | 2021 | 188 | 0.180 |
Why?
| | Administration, Oral | 4 | 2019 | 786 | 0.180 |
Why?
| | Fallopian Tube Diseases | 1 | 1998 | 5 | 0.180 |
Why?
| | Pregnancy, Tubal | 1 | 1998 | 4 | 0.180 |
Why?
| | Metabolome | 1 | 2022 | 299 | 0.180 |
Why?
| | Immune System | 1 | 2020 | 194 | 0.180 |
Why?
| | Munchausen Syndrome by Proxy | 1 | 1998 | 3 | 0.180 |
Why?
| | Abortifacient Agents, Nonsteroidal | 1 | 1998 | 20 | 0.180 |
Why?
| | Plant Extracts | 1 | 2020 | 169 | 0.180 |
Why?
| | Alcoholism | 3 | 2011 | 797 | 0.180 |
Why?
| | Dietary Carbohydrates | 1 | 2019 | 164 | 0.180 |
Why?
| | Anticonvulsants | 1 | 2020 | 188 | 0.170 |
Why?
| | Snake Bites | 1 | 1999 | 59 | 0.170 |
Why?
| | Sulfasalazine | 1 | 1998 | 21 | 0.170 |
Why?
| | Sex Factors | 5 | 2022 | 1918 | 0.170 |
Why?
| | Drug Antagonism | 2 | 2009 | 8 | 0.170 |
Why?
| | Dyspnea | 1 | 1999 | 199 | 0.170 |
Why?
| | Chi-Square Distribution | 2 | 2017 | 566 | 0.170 |
Why?
| | Faculty, Medical | 1 | 2021 | 256 | 0.170 |
Why?
| | Fellowships and Scholarships | 1 | 2021 | 243 | 0.170 |
Why?
| | Drug Interactions | 4 | 2014 | 372 | 0.160 |
Why?
| | Gastrointestinal Agents | 1 | 1998 | 58 | 0.160 |
Why?
| | Simulation Training | 1 | 2018 | 65 | 0.160 |
Why?
| | Drug Therapy, Combination | 3 | 2011 | 1012 | 0.160 |
Why?
| | Methotrexate | 1 | 1998 | 243 | 0.160 |
Why?
| | Hypnotics and Sedatives | 1 | 1998 | 135 | 0.160 |
Why?
| | Out-of-Hospital Cardiac Arrest | 1 | 2018 | 98 | 0.160 |
Why?
| | Survival Rate | 3 | 2013 | 1807 | 0.160 |
Why?
| | Incidence | 4 | 2013 | 2504 | 0.160 |
Why?
| | Continuity of Patient Care | 1 | 2020 | 275 | 0.160 |
Why?
| | Ammonium Compounds | 1 | 2016 | 4 | 0.160 |
Why?
| | Peptide Fragments | 1 | 2021 | 718 | 0.160 |
Why?
| | Dietary Fats | 1 | 2019 | 353 | 0.160 |
Why?
| | Pain Management | 2 | 2017 | 300 | 0.150 |
Why?
| | Fluorides | 1 | 2016 | 49 | 0.150 |
Why?
| | Cytochrome P-450 CYP2E1 Inhibitors | 1 | 2016 | 5 | 0.150 |
Why?
| | Clinical Trials as Topic | 2 | 2012 | 999 | 0.150 |
Why?
| | Metabolic Clearance Rate | 2 | 2019 | 124 | 0.150 |
Why?
| | Half-Life | 2 | 2019 | 159 | 0.150 |
Why?
| | Prenatal Care | 1 | 2019 | 260 | 0.150 |
Why?
| | Ventricular Fibrillation | 1 | 2016 | 66 | 0.150 |
Why?
| | Mice | 7 | 2009 | 15537 | 0.150 |
Why?
| | Pharmacovigilance | 1 | 2015 | 15 | 0.150 |
Why?
| | Predictive Value of Tests | 3 | 2015 | 1971 | 0.150 |
Why?
| | Cohort Studies | 6 | 2017 | 5112 | 0.140 |
Why?
| | Herniorrhaphy | 1 | 2016 | 40 | 0.140 |
Why?
| | Energy Intake | 1 | 2019 | 516 | 0.140 |
Why?
| | Survival Analysis | 3 | 2010 | 1358 | 0.140 |
Why?
| | Pilot Projects | 1 | 2020 | 1441 | 0.140 |
Why?
| | Genetic Variation | 1 | 2020 | 801 | 0.140 |
Why?
| | Milk | 1 | 2016 | 140 | 0.140 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2015 | 70 | 0.140 |
Why?
| | Fatal Outcome | 2 | 2013 | 305 | 0.140 |
Why?
| | Hemodialysis Units, Hospital | 1 | 1994 | 5 | 0.140 |
Why?
| | Calcium | 2 | 2016 | 1203 | 0.140 |
Why?
| | Ondansetron | 1 | 2014 | 14 | 0.140 |
Why?
| | Liver Failure, Acute | 1 | 2015 | 65 | 0.130 |
Why?
| | Child Behavior | 1 | 2017 | 249 | 0.130 |
Why?
| | Cytochrome P-450 CYP2D6 | 1 | 2014 | 22 | 0.130 |
Why?
| | Patient Simulation | 1 | 2014 | 34 | 0.130 |
Why?
| | Genome-Wide Association Study | 1 | 2020 | 1036 | 0.130 |
Why?
| | Hydrocodone | 1 | 2014 | 14 | 0.130 |
Why?
| | Total Quality Management | 1 | 1994 | 58 | 0.130 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2015 | 85 | 0.130 |
Why?
| | Physicians | 2 | 2020 | 771 | 0.130 |
Why?
| | Models, Biological | 2 | 2015 | 1763 | 0.130 |
Why?
| | Transaminases | 1 | 2014 | 26 | 0.130 |
Why?
| | Acute Pain | 1 | 2014 | 30 | 0.130 |
Why?
| | Oxycodone | 1 | 2014 | 48 | 0.130 |
Why?
| | Internship and Residency | 2 | 2014 | 1026 | 0.130 |
Why?
| | Remote Consultation | 1 | 2014 | 40 | 0.130 |
Why?
| | Curriculum | 1 | 2021 | 886 | 0.130 |
Why?
| | Guanfacine | 1 | 2013 | 2 | 0.130 |
Why?
| | Clonidine | 1 | 2013 | 24 | 0.130 |
Why?
| | Prognosis | 3 | 2011 | 3549 | 0.130 |
Why?
| | International Normalized Ratio | 2 | 2011 | 46 | 0.130 |
Why?
| | Cesium | 1 | 2013 | 18 | 0.120 |
Why?
| | Vitamins | 1 | 2015 | 164 | 0.120 |
Why?
| | Indazoles | 1 | 2014 | 71 | 0.120 |
Why?
| | Pregnancy Complications | 1 | 2019 | 474 | 0.120 |
Why?
| | Walking | 1 | 2017 | 434 | 0.120 |
Why?
| | Decision Support Systems, Clinical | 1 | 2015 | 162 | 0.120 |
Why?
| | Food | 1 | 2015 | 166 | 0.120 |
Why?
| | Deoxycholic Acid | 1 | 2013 | 21 | 0.120 |
Why?
| | Lethargy | 1 | 2012 | 6 | 0.120 |
Why?
| | Duloxetine Hydrochloride | 1 | 2012 | 8 | 0.120 |
Why?
| | Dabigatran | 1 | 2012 | 30 | 0.120 |
Why?
| | Attitude of Health Personnel | 1 | 2020 | 1029 | 0.120 |
Why?
| | Athletic Performance | 1 | 2013 | 53 | 0.120 |
Why?
| | Pain Measurement | 4 | 2019 | 527 | 0.120 |
Why?
| | Chlorides | 1 | 2013 | 137 | 0.120 |
Why?
| | Sleep Stages | 1 | 2012 | 71 | 0.120 |
Why?
| | Sulfhydryl Reagents | 1 | 2012 | 11 | 0.110 |
Why?
| | Marijuana Abuse | 1 | 2015 | 220 | 0.110 |
Why?
| | Pyrazoles | 1 | 2016 | 401 | 0.110 |
Why?
| | Mycoses | 1 | 2013 | 74 | 0.110 |
Why?
| | Tachycardia | 1 | 2012 | 65 | 0.110 |
Why?
| | Dizziness | 1 | 2012 | 77 | 0.110 |
Why?
| | Arsenicals | 1 | 2012 | 21 | 0.110 |
Why?
| | Data Collection | 2 | 2013 | 667 | 0.110 |
Why?
| | Sampling Studies | 1 | 2012 | 105 | 0.110 |
Why?
| | Patient Discharge | 2 | 2016 | 820 | 0.110 |
Why?
| | Accidental Falls | 2 | 2011 | 164 | 0.110 |
Why?
| | Drug Combinations | 1 | 2013 | 303 | 0.110 |
Why?
| | Laparoscopy | 1 | 2016 | 395 | 0.110 |
Why?
| | Information Systems | 1 | 2011 | 69 | 0.110 |
Why?
| | Sulfides | 1 | 2012 | 102 | 0.110 |
Why?
| | Arabia | 1 | 2011 | 2 | 0.110 |
Why?
| | Hepatic Encephalopathy | 1 | 2011 | 20 | 0.110 |
Why?
| | Levamisole | 1 | 2011 | 20 | 0.110 |
Why?
| | Marijuana Smoking | 1 | 2015 | 233 | 0.110 |
Why?
| | Structure-Activity Relationship | 1 | 2012 | 530 | 0.100 |
Why?
| | Dietary Supplements | 1 | 2015 | 465 | 0.100 |
Why?
| | Follow-Up Studies | 3 | 2010 | 4911 | 0.100 |
Why?
| | Immunocompromised Host | 1 | 2013 | 210 | 0.100 |
Why?
| | Sports | 1 | 2013 | 177 | 0.100 |
Why?
| | Drug Contamination | 1 | 2011 | 60 | 0.100 |
Why?
| | Pharmacogenetics | 1 | 2012 | 139 | 0.100 |
Why?
| | Molecular Structure | 1 | 2012 | 470 | 0.100 |
Why?
| | Universities | 1 | 2013 | 354 | 0.100 |
Why?
| | Glipizide | 1 | 2010 | 7 | 0.100 |
Why?
| | Hepatitis, Alcoholic | 1 | 2010 | 12 | 0.100 |
Why?
| | Laboratories, Hospital | 1 | 2010 | 15 | 0.100 |
Why?
| | Troponin | 1 | 2010 | 47 | 0.100 |
Why?
| | Glyburide | 1 | 2010 | 45 | 0.100 |
Why?
| | Crowding | 1 | 2010 | 39 | 0.100 |
Why?
| | Watchful Waiting | 1 | 2010 | 57 | 0.100 |
Why?
| | Drug Prescriptions | 2 | 2016 | 264 | 0.100 |
Why?
| | Quetiapine Fumarate | 1 | 2009 | 27 | 0.090 |
Why?
| | Adjuvants, Immunologic | 1 | 2011 | 223 | 0.090 |
Why?
| | Dibenzothiazepines | 1 | 2009 | 19 | 0.090 |
Why?
| | Aripiprazole | 1 | 2009 | 17 | 0.090 |
Why?
| | Body Weight | 1 | 2014 | 990 | 0.090 |
Why?
| | Risperidone | 1 | 2009 | 26 | 0.090 |
Why?
| | Workload | 1 | 2010 | 135 | 0.090 |
Why?
| | Potassium | 1 | 2009 | 149 | 0.090 |
Why?
| | Dogs | 1 | 2010 | 417 | 0.090 |
Why?
| | Role | 1 | 2009 | 32 | 0.090 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2011 | 197 | 0.090 |
Why?
| | Head Protective Devices | 1 | 2009 | 19 | 0.090 |
Why?
| | Efficiency, Organizational | 1 | 2010 | 133 | 0.090 |
Why?
| | Renal Dialysis | 1 | 2013 | 379 | 0.090 |
Why?
| | Quality Control | 1 | 2009 | 154 | 0.090 |
Why?
| | Health Services Accessibility | 1 | 2015 | 798 | 0.090 |
Why?
| | Glutathione | 3 | 2022 | 329 | 0.090 |
Why?
| | Acidosis | 2 | 2006 | 92 | 0.090 |
Why?
| | Military Personnel | 1 | 2014 | 417 | 0.090 |
Why?
| | Diarrhea | 1 | 2009 | 172 | 0.090 |
Why?
| | Body Temperature | 1 | 2009 | 253 | 0.090 |
Why?
| | Skiing | 1 | 2009 | 40 | 0.090 |
Why?
| | Bibliometrics | 1 | 2009 | 63 | 0.090 |
Why?
| | Informed Consent | 2 | 2006 | 160 | 0.090 |
Why?
| | Pharmacy Service, Hospital | 1 | 2009 | 85 | 0.090 |
Why?
| | Quality Indicators, Health Care | 1 | 2011 | 297 | 0.090 |
Why?
| | Acetone | 1 | 2008 | 8 | 0.090 |
Why?
| | Hair Preparations | 1 | 2008 | 2 | 0.090 |
Why?
| | Adhesiveness | 1 | 2008 | 17 | 0.090 |
Why?
| | Bacitracin | 1 | 2008 | 7 | 0.090 |
Why?
| | Nylons | 1 | 2008 | 12 | 0.090 |
Why?
| | Students | 1 | 2013 | 518 | 0.080 |
Why?
| | Propylene Glycols | 1 | 2008 | 28 | 0.080 |
Why?
| | Cause of Death | 1 | 2010 | 399 | 0.080 |
Why?
| | Withholding Treatment | 1 | 2008 | 72 | 0.080 |
Why?
| | Quinolones | 1 | 2009 | 102 | 0.080 |
Why?
| | Substance Abuse Detection | 2 | 2021 | 61 | 0.080 |
Why?
| | Equipment Design | 1 | 2009 | 532 | 0.080 |
Why?
| | Cellulose | 1 | 2008 | 65 | 0.080 |
Why?
| | Glycerol | 1 | 2008 | 94 | 0.080 |
Why?
| | Nephelometry and Turbidimetry | 1 | 2007 | 16 | 0.080 |
Why?
| | Drug Synergism | 1 | 2008 | 349 | 0.080 |
Why?
| | Polypharmacy | 1 | 2008 | 74 | 0.080 |
Why?
| | Laboratories | 1 | 2008 | 97 | 0.080 |
Why?
| | Hospitalization | 2 | 2011 | 1774 | 0.080 |
Why?
| | Formates | 1 | 2006 | 15 | 0.080 |
Why?
| | Kidney Transplantation | 1 | 2013 | 546 | 0.080 |
Why?
| | Phosphates | 1 | 2008 | 176 | 0.080 |
Why?
| | Defibrillators | 1 | 2006 | 20 | 0.080 |
Why?
| | Methanol | 1 | 2006 | 39 | 0.080 |
Why?
| | Tissue Distribution | 2 | 2019 | 349 | 0.080 |
Why?
| | Telemedicine | 1 | 2014 | 595 | 0.080 |
Why?
| | Blindness | 1 | 2006 | 34 | 0.080 |
Why?
| | Combined Modality Therapy | 1 | 2009 | 1191 | 0.080 |
Why?
| | Research | 2 | 2011 | 445 | 0.080 |
Why?
| | Naproxen | 1 | 2006 | 13 | 0.070 |
Why?
| | Ipecac | 1 | 2005 | 8 | 0.070 |
Why?
| | Statistics, Nonparametric | 1 | 2007 | 444 | 0.070 |
Why?
| | Probability | 2 | 2010 | 325 | 0.070 |
Why?
| | Spinal Diseases | 1 | 2006 | 47 | 0.070 |
Why?
| | Periodicals as Topic | 1 | 2009 | 233 | 0.070 |
Why?
| | Respiratory Insufficiency | 1 | 2009 | 293 | 0.070 |
Why?
| | Health Services for the Aged | 1 | 2006 | 79 | 0.070 |
Why?
| | Population Dynamics | 1 | 2006 | 136 | 0.070 |
Why?
| | Aging | 2 | 2014 | 1690 | 0.070 |
Why?
| | Vasopressins | 1 | 2006 | 143 | 0.070 |
Why?
| | Respiration, Artificial | 1 | 2009 | 563 | 0.070 |
Why?
| | Epinephrine | 1 | 2006 | 183 | 0.070 |
Why?
| | Haplorhini | 1 | 2005 | 58 | 0.070 |
Why?
| | Premedication | 1 | 2005 | 44 | 0.070 |
Why?
| | Ibuprofen | 1 | 2006 | 79 | 0.070 |
Why?
| | Geriatrics | 1 | 2006 | 79 | 0.070 |
Why?
| | Hospitals, University | 1 | 2006 | 189 | 0.070 |
Why?
| | Spine | 1 | 2006 | 137 | 0.070 |
Why?
| | Practice Guidelines as Topic | 2 | 2014 | 1524 | 0.070 |
Why?
| | Blood Glucose | 2 | 2019 | 1904 | 0.070 |
Why?
| | Water | 1 | 2008 | 428 | 0.070 |
Why?
| | Single-Blind Method | 1 | 2005 | 282 | 0.070 |
Why?
| | Fluoride Poisoning | 1 | 2004 | 4 | 0.060 |
Why?
| | Motivation | 1 | 2009 | 529 | 0.060 |
Why?
| | Risk | 1 | 2007 | 926 | 0.060 |
Why?
| | Resuscitation | 1 | 2006 | 289 | 0.060 |
Why?
| | Magnesium | 1 | 2004 | 155 | 0.060 |
Why?
| | Guidelines as Topic | 1 | 2005 | 281 | 0.060 |
Why?
| | Pregnancy | 3 | 2021 | 5554 | 0.060 |
Why?
| | Mycophenolic Acid | 1 | 2004 | 85 | 0.060 |
Why?
| | Health Policy | 1 | 2006 | 354 | 0.060 |
Why?
| | Sheep | 1 | 2006 | 748 | 0.060 |
Why?
| | Survival | 1 | 2003 | 39 | 0.060 |
Why?
| | Aspirin | 1 | 2006 | 342 | 0.060 |
Why?
| | Patient Participation | 1 | 2006 | 362 | 0.060 |
Why?
| | Lactates | 1 | 2022 | 92 | 0.060 |
Why?
| | Urban Population | 2 | 2019 | 421 | 0.060 |
Why?
| | Prevalence | 3 | 2015 | 2438 | 0.060 |
Why?
| | Culture Techniques | 1 | 2001 | 91 | 0.060 |
Why?
| | Sex Distribution | 2 | 2015 | 390 | 0.060 |
Why?
| | Internet | 1 | 2007 | 656 | 0.050 |
Why?
| | Blood Physiological Phenomena | 1 | 2021 | 15 | 0.050 |
Why?
| | Neural Conduction | 1 | 2001 | 82 | 0.050 |
Why?
| | Academic Medical Centers | 2 | 2016 | 414 | 0.050 |
Why?
| | Hirudins | 1 | 2021 | 48 | 0.050 |
Why?
| | Breast Neoplasms | 1 | 2013 | 1929 | 0.050 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2020 | 29 | 0.050 |
Why?
| | Infusions, Parenteral | 1 | 2020 | 42 | 0.050 |
Why?
| | Pirenzepine | 1 | 1999 | 10 | 0.050 |
Why?
| | Scorpions | 1 | 1999 | 2 | 0.050 |
Why?
| | South America | 1 | 1999 | 40 | 0.050 |
Why?
| | Certification | 1 | 2020 | 114 | 0.050 |
Why?
| | Immunosuppressive Agents | 1 | 2004 | 690 | 0.050 |
Why?
| | Blood Cell Count | 2 | 2013 | 58 | 0.050 |
Why?
| | Temperature | 1 | 2022 | 616 | 0.050 |
Why?
| | Biological Availability | 1 | 2019 | 138 | 0.050 |
Why?
| | Rupture, Spontaneous | 1 | 1998 | 18 | 0.050 |
Why?
| | Narcotics | 1 | 1999 | 64 | 0.050 |
Why?
| | Videotape Recording | 1 | 2018 | 31 | 0.040 |
Why?
| | Postprandial Period | 1 | 2019 | 110 | 0.040 |
Why?
| | Manikins | 1 | 2018 | 28 | 0.040 |
Why?
| | Sorption Detoxification | 1 | 1998 | 3 | 0.040 |
Why?
| | Dietary Proteins | 1 | 2019 | 125 | 0.040 |
Why?
| | Cholinesterase Inhibitors | 1 | 1998 | 22 | 0.040 |
Why?
| | Central Nervous System Depressants | 1 | 1999 | 115 | 0.040 |
Why?
| | North America | 1 | 1999 | 269 | 0.040 |
Why?
| | Laparotomy | 1 | 1998 | 114 | 0.040 |
Why?
| | Feedback | 1 | 2018 | 153 | 0.040 |
Why?
| | Lipids | 1 | 2022 | 638 | 0.040 |
Why?
| | Analysis of Variance | 1 | 2001 | 1451 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2019 | 499 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2021 | 1322 | 0.040 |
Why?
| | Maternal Health Services | 1 | 2019 | 77 | 0.040 |
Why?
| | Bipolar Disorder | 1 | 1999 | 207 | 0.040 |
Why?
| | Socioeconomic Factors | 2 | 2015 | 1163 | 0.040 |
Why?
| | Central Nervous System | 1 | 1999 | 261 | 0.040 |
Why?
| | Triglycerides | 1 | 2019 | 551 | 0.040 |
Why?
| | Registries | 2 | 2010 | 1969 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2019 | 957 | 0.040 |
Why?
| | Hallucinogens | 1 | 2017 | 70 | 0.040 |
Why?
| | Dialysis | 1 | 2015 | 23 | 0.040 |
Why?
| | Centrifugation | 1 | 2015 | 32 | 0.040 |
Why?
| | Verapamil | 1 | 2014 | 34 | 0.030 |
Why?
| | Tennessee | 1 | 1994 | 46 | 0.030 |
Why?
| | Observation | 1 | 2014 | 57 | 0.030 |
Why?
| | Hematocrit | 1 | 1994 | 99 | 0.030 |
Why?
| | Syndrome | 1 | 2015 | 352 | 0.030 |
Why?
| | International Classification of Diseases | 1 | 2015 | 130 | 0.030 |
Why?
| | Anesthetics, Local | 1 | 2014 | 88 | 0.030 |
Why?
| | Warfare | 1 | 2014 | 72 | 0.030 |
Why?
| | Erythropoietin | 1 | 1994 | 80 | 0.030 |
Why?
| | Program Evaluation | 1 | 2018 | 870 | 0.030 |
Why?
| | Protein Binding | 1 | 2020 | 2018 | 0.030 |
Why?
| | Injections, Intralesional | 1 | 2013 | 31 | 0.030 |
Why?
| | Hospitals, Veterans | 1 | 1994 | 208 | 0.030 |
Why?
| | Salicylates | 1 | 2013 | 32 | 0.030 |
Why?
| | Urinalysis | 1 | 2013 | 62 | 0.030 |
Why?
| | Iron | 1 | 1994 | 235 | 0.030 |
Why?
| | Hemoglobins | 1 | 1994 | 282 | 0.030 |
Why?
| | Nursing Staff, Hospital | 1 | 1994 | 150 | 0.030 |
Why?
| | Therapeutic Irrigation | 1 | 2012 | 70 | 0.030 |
Why?
| | Long QT Syndrome | 1 | 2013 | 87 | 0.030 |
Why?
| | Receptors, Opioid, mu | 1 | 2012 | 62 | 0.030 |
Why?
| | Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2011 | 5 | 0.030 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2012 | 117 | 0.030 |
Why?
| | Agranulocytosis | 1 | 2011 | 33 | 0.030 |
Why?
| | False Negative Reactions | 1 | 2011 | 65 | 0.030 |
Why?
| | Disease Outbreaks | 1 | 2014 | 293 | 0.030 |
Why?
| | Insulin Resistance | 1 | 2019 | 1163 | 0.030 |
Why?
| | Toothache | 1 | 2010 | 5 | 0.030 |
Why?
| | Computer Simulation | 1 | 2015 | 923 | 0.030 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2011 | 145 | 0.030 |
Why?
| | Fluid Therapy | 1 | 2012 | 151 | 0.030 |
Why?
| | Immunoassay | 1 | 2011 | 106 | 0.030 |
Why?
| | Leukoencephalopathies | 1 | 2011 | 32 | 0.030 |
Why?
| | Drug Administration Routes | 1 | 2010 | 46 | 0.020 |
Why?
| | Quality of Health Care | 1 | 2015 | 631 | 0.020 |
Why?
| | Insurance Coverage | 1 | 2012 | 219 | 0.020 |
Why?
| | Models, Theoretical | 1 | 1994 | 595 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2010 | 226 | 0.020 |
Why?
| | Neurologic Examination | 1 | 2010 | 125 | 0.020 |
Why?
| | Patient Education as Topic | 1 | 1994 | 720 | 0.020 |
Why?
| | Age Distribution | 1 | 2010 | 382 | 0.020 |
Why?
| | Kidney Failure, Chronic | 1 | 1994 | 512 | 0.020 |
Why?
| | Intestines | 1 | 2012 | 320 | 0.020 |
Why?
| | Precision Medicine | 1 | 2012 | 291 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2012 | 636 | 0.020 |
Why?
| | Safety | 1 | 2010 | 314 | 0.020 |
Why?
| | Triage | 1 | 2010 | 210 | 0.020 |
Why?
| | Seasons | 1 | 2010 | 436 | 0.020 |
Why?
| | Clinical Competence | 1 | 2014 | 948 | 0.020 |
Why?
| | Ethanol | 1 | 2012 | 727 | 0.020 |
Why?
| | Bilirubin | 1 | 2007 | 84 | 0.020 |
Why?
| | Regression Analysis | 1 | 2010 | 1072 | 0.020 |
Why?
| | Pulse | 1 | 2006 | 33 | 0.020 |
Why?
| | Metabolomics | 1 | 2012 | 537 | 0.020 |
Why?
| | Disease Management | 1 | 2011 | 603 | 0.020 |
Why?
| | Blastomycosis | 1 | 2006 | 8 | 0.020 |
Why?
| | Genotype | 1 | 2012 | 1825 | 0.020 |
Why?
| | Contraindications | 1 | 2006 | 93 | 0.020 |
Why?
| | Coronary Circulation | 1 | 2006 | 147 | 0.020 |
Why?
| | Amyloidosis | 1 | 2006 | 39 | 0.020 |
Why?
| | Biopsy, Fine-Needle | 1 | 2006 | 66 | 0.020 |
Why?
| | European Union | 1 | 2005 | 10 | 0.020 |
Why?
| | Infant, Newborn | 2 | 2007 | 5230 | 0.020 |
Why?
| | Electric Countershock | 1 | 2006 | 139 | 0.020 |
Why?
| | Disaster Planning | 1 | 2006 | 79 | 0.020 |
Why?
| | Fever | 1 | 2007 | 300 | 0.020 |
Why?
| | Emergencies | 1 | 2006 | 165 | 0.020 |
Why?
| | United States Food and Drug Administration | 1 | 2005 | 185 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 2006 | 656 | 0.020 |
Why?
| | Renal Insufficiency | 1 | 2006 | 133 | 0.020 |
Why?
| | Pharmaceutical Preparations | 1 | 2006 | 167 | 0.020 |
Why?
| | Swine | 1 | 2006 | 734 | 0.020 |
Why?
| | Brain Injuries | 1 | 2009 | 471 | 0.020 |
Why?
| | Up-Regulation | 1 | 2007 | 900 | 0.020 |
Why?
| | Phenotype | 1 | 2012 | 2875 | 0.020 |
Why?
| | Mice, Inbred ICR | 1 | 2004 | 116 | 0.020 |
Why?
| | Lupus Nephritis | 1 | 2004 | 55 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2004 | 1143 | 0.010 |
Why?
| | Miosis | 1 | 1999 | 3 | 0.010 |
Why?
| | Pupil | 1 | 1999 | 14 | 0.010 |
Why?
| | Blood Pressure | 1 | 2006 | 1680 | 0.010 |
Why?
| | Hemodynamics | 1 | 2004 | 1085 | 0.010 |
Why?
| | Chronic Disease | 1 | 2004 | 1674 | 0.010 |
Why?
| | Algorithms | 1 | 2004 | 1550 | 0.010 |
Why?
| | Neoplasms | 1 | 2006 | 2139 | 0.010 |
Why?
|
|
Heard's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|